Resona Asset Management Co. Ltd. Makes New $8.64 Million Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Resona Asset Management Co. Ltd. bought a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 36,656 shares of the biopharmaceutical company’s stock, valued at approximately $8,637,000.

Several other institutional investors have also recently made changes to their positions in the company. Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals in the 4th quarter worth about $1,045,822,000. Norges Bank purchased a new stake in shares of Alnylam Pharmaceuticals in the fourth quarter worth approximately $577,941,000. Raymond James Financial Inc. bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter worth approximately $65,295,000. Jennison Associates LLC purchased a new position in Alnylam Pharmaceuticals during the 4th quarter valued at $61,160,000. Finally, Proficio Capital Partners LLC grew its position in Alnylam Pharmaceuticals by 25,929.6% in the 4th quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after acquiring an additional 192,916 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insider Transactions at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 52,592 shares of the firm’s stock in a transaction on Monday, January 27th. The stock was sold at an average price of $285.00, for a total value of $14,988,720.00. Following the completion of the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This trade represents a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total value of $3,093,750.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. Company insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 1.2 %

Shares of NASDAQ:ALNY opened at $232.95 on Tuesday. The business’s 50-day moving average is $258.16 and its 200 day moving average is $259.83. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals, Inc. has a 1 year low of $141.98 and a 1 year high of $304.39. The firm has a market capitalization of $30.30 billion, a P/E ratio of -107.35 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, research analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts have recently weighed in on ALNY shares. Citigroup lifted their target price on Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the stock a “buy” rating in a research report on Friday, March 21st. JPMorgan Chase & Co. upgraded shares of Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $280.00 to $328.00 in a report on Monday, March 24th. HC Wainwright restated a “buy” rating and issued a $500.00 target price on shares of Alnylam Pharmaceuticals in a research note on Wednesday, April 2nd. Sanford C. Bernstein decreased their price target on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Finally, William Blair reissued an “outperform” rating on shares of Alnylam Pharmaceuticals in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have given a buy rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $316.25.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.